Welcome to our dedicated page for Coeptis Therapeutics Holdings news (Ticker: $COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coeptis Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coeptis Therapeutics Holdings's position in the market.
Coeptis Therapeutics Holdings, a biopharmaceutical company, will present its innovative universal allogeneic SNAP-CAR NK cell therapy at the ISCT 2024 conference. This therapy has the potential to target multiple antigens, potentially avoiding toxicities and relapse. Coeptis expanded its license agreement for SNAP-CAR to include natural killer cells, aiming to develop a safer and cost-effective cellular therapy. The company's presentation at ISCT 2024 signifies a significant step towards universalizing the treatment of various diseases.
Coeptis Therapeutics Holdings, a biopharmaceutical company, will present data on the development of SNAP-CAR NK cells at the ASGCT Annual Meeting. The Company aims to revolutionize cancer treatment with a universal targeted cell therapy that eliminates the need for HLA matching.
